维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

7篇 您的检索式：作者名="Ecca"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Setzu Modeling and Simulation of an Arti?cial Stock Option Market显示文摘	Ecca Marchesi		0，，32：	1
	2	The Denver school- based adolescent hepatitis B vaccination program; A Cost analysis with fist simulation显示文摘	Robert R D Edward J H Ret)ecca S	1997	Am J Public Health1997，，17：	1
	3	Modeling and simulation of an artificial stock Option market显示文摘	Ecca S Marchesi M Setzu A	2008	Computational Economics2008，32，12：	1
	4	The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines显示文摘Fluoropyrimidines(FP)are given in the combination treatment of the advanced disease or as monotherapy in the neo-adjuvant and adjuvant treatment of colorectal cancerand other solid tumors including breast,head and neck and gastric cancer.FP present a narrow therapeutic index with 10 to 26% of patients experiencing acute severe or life-threatening toxicity.With the high number of patients receiving FP-based therapies,and the significant effects of toxicities on their quality of life,the prevention of FP-related adverse events is of major clinical interest.Host genetic variants in the rate limiting enzyme dihydropyrimidine dehydrogenase(DPYD)gene are related to the occurrence of extremely severe,early onset toxicity in FP treated patients.The pre-treatment diagnostic test of 4 DPYD genetic polymorphisms is suggested by the currently available pharmacogenetic guidelines.Several prospective implementation projects are ongoing to support the introduction of up-front genotyping of the patients in clinical practice.Multiple pharmacogenetic studies tried to assess the predictive role of other polymorphisms in genes involved in the FP pharmacokinetics/pharmacodynamic pathways,TYMS and MTHFR,but no additional clinically validated genetic markers of toxicity are available to date.The development of next-generation sequencing platforms opens new possibilities to highlight previously unreported genetic markers.Moreover,the investigation of the genetic variation in the patients immunological system,a pivotal target in cancer treatment,could bring notable advances in the field.This review will describe the most recent literature on the use of pharmacogenetics to increase the safety of a treatment based on FP administration in colorectal cancer patients.	Elena De Mattia Rossana Roncato Chiara Dalle Fratte Fabrizio Ecca Giuseppe Toffoli Erika Cecchin	2019	Cancer Drug Resistance2019，2，1：	1
	5	Modeling and Simulation of an Artificial Stock Option Market显示文摘	Sabrina Ecca Michele Marchesi Alessio Setzu	2008	Computational Economics2008，，1：	1
	6	Modeling and simulation of an artificial stock option market 显示文摘	Ecca S Marchesi M Setzu A	2008	Computational Economics2008，32，12：	1
	7	Bluetongue: A Hypothesis of Control Strategy through Decrease of Culicoides and Their Associated Damage in Farm显示文摘	Rolesu Sandro Aloi Daniela Cappai Stefano Mereu Piras Pierpaola Fois Francesco Satta Giuseppe Palmas Costantino Ecca Anna Rita Pulina Giuseppe	2013	Journal of Life Sciences2013，7，1：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费